Acorda Therapeutics Inc Stock Research

Market Summary

USD0.630.00

Delayed

0.00%

ACOR Stock Price

ACOR RSI Chart

ACOR Valuation

Market Cap

15.2M

Price/Earnings (Trailing)

-0.14

Price/Sales (Trailing)

0.12

EV/EBITDA

0.44

Price/Free Cashflow

-0.56

ACOR Price/Sales (Trailing)

ACOR Profitability

EBT Margin

-61.03%

Return on Equity

-139.47%

Return on Assets

-26.87%

Free Cashflow Yield

-177.05%

ACOR Fundamentals

ACOR Revenue

Revenue (TTM)

124.1M

Revenue Y/Y

6.53%

Revenue Q/Q

7.92%

ACOR Earnings

Earnings (TTM)

-105.7M

Earnings Y/Y

48.82%

Earnings Q/Q

70.32%

Price Action

52 Week Range

0.261.86

(Low)(High)

Last 7 days

-37.5%

Last 30 days

-28.2%

Last 90 days

13.6%

Trailing 12 Months

-62.6%

ACOR Financial Health

Current Ratio

1.71

Debt/Equity

1.72

Debt/Cashflow

-0.22

ACOR Investor Care

Shares Dilution (1Y)

118.22%

Diluted EPS (TTM)

-6.82

Peers (Alternatives to Acorda Therapeutics)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
AMGN	125.3B	26.3B	-2.75%	3.76%	19.12	4.76	1.32%	11.18%
GILD	99.6B	27.3B	-8.96%	41.01%	21.68	3.65	-0.09%	-26.23%
MRNA	58.4B	19.3B	-12.76%	1.00%	6.99	3.03	4.29%	-31.47%
BIIB	38.3B	10.2B	-9.67%	32.94%	12.57	3.76	-7.36%	95.80%
MID-CAP
NBIX	9.1B	1.5B	-9.09%	3.35%	58.87	6.11	31.34%	72.43%
DNLI	3.2B	108.5M	-21.10%	-19.55%	-9.78	29.38	122.90%	-12.19%
BEAM	2.5B	60.9M	-18.47%	-36.46%	-8.76	41.55	17.51%	22.00%
BBIO	2.1B	107.9M	22.95%	67.45%	-4.29	19.27	54.84%	17.36%
SMALL-CAP
RCUS	1.2B	112.0M	-14.86%	-46.41%	-4.63	11.04	-70.76%	-603.77%
REPL	1.1B	7.0M	-22.18%	24.65%	-7.11	158.97	131.81%	-45.39%
FATE	541.9M	96.3M	-12.99%	-82.24%	-1.92	5.63	72.44%	-32.79%
NVAX	513.7M	2.0B	-39.67%	-92.01%	-0.78	0.26	72.89%	62.27%
SGMO	355.3M	111.3M	-30.55%	-58.78%	-1.85	3.19	0.54%	-7.86%
VXRT	101.4M	159.0K	-16.47%	-82.96%	-0.97	637.62	-86.46%	-64.56%
IBIO	25.1M	-	94.03%	-77.12%	-0.31	3.21	0.51%	-185.61%

Financials for Acorda Therapeutics

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	-4.4%	118,566,000	124,063,000	122,008,000	122,742,000	129,071,000
S&GA Expenses	-2.0%	106,256,000	108,442,000	115,068,000	117,369,000	124,399,000
R&D Expenses	-2.7%	5,804,000	5,968,000	6,516,000	7,365,000	10,420,000
Costs and Expenses	-10.1%	153,906,000	171,229,000	187,194,000	189,702,000	208,109,000
EBITDA	58.1%	-12,640,000	-30,149,000	-64,055,000	-76,139,000	-
EBITDA Margin	58.8%	-0.10	-0.25	-0.52	-0.59	-
Earnings Before Taxes	53.5%	-35,247,000	-75,720,000	-93,458,000	-96,734,000	-109,074,000
EBT Margin	20.3%	-0.61	-0.77	-0.79	-0.85	-
Interest Expenses	1.2%	30,200,000	29,839,000	29,541,000	29,772,000	30,035,000
Net Income	37.6%	-65,916,000	-105,671,000	-118,888,000	-95,070,000	-104,000,000
Net Income Margin	12.6%	-0.85	-0.97	-0.77	-0.81	-
Free Cahsflow	21.0%	-26,887,000	-34,033,000	-28,273,000	-41,513,000	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	0.6%	396	393	406	424	455
Current Assets	14.5%	82.00	72.00	77.00	80.00	102
Cash Equivalents	81.4%	38.00	21.00	23.00	32.00	46.00
Inventory	-16.4%	13.00	15.00	15.00	15.00	19.00
Net PPE	-7.9%	3.00	3.00	3.00	4.00	4.00
Current Liabilities	-9.7%	38.00	42.00	41.00	46.00	54.00
Long Term Debt	-	151	-	-	-	-
Shareholder's Equity	23.6%	94.00	76.00	88.00	128	151
Retained Earnings	2.0%	-936	-955	-941	-894	-870
Additional Paid-In Capital	0.0%	1,030	1,030	1,029	1,024	1,023
Accumulated Depreciation	-	35.00	-	-	-	-
Shares Outstanding	44.7%	24.00	17.00	13.00	-	-

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	21.8%	-20.92	-26.75	-33.92	-28.10	-41.35
Share Based Compensation	-17.1%	1.00	2.00	2.00	3.00	3.00
Cashflow From Investing	47.7%	-0.14	-0.26	-0.11	-0.18	74.00
Cashflow From Financing	-	-69.65	-	-	-	-

Risks for ACOR

What is the probability of a big loss on ACOR?

100%

Probability that Acorda Therapeutics stock will be more than 20% underwater in next one year

100%

Probability that Acorda Therapeutics stock will be more than 30% underwater in next one year.

91.5%

Probability that Acorda Therapeutics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ACOR drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Acorda Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for ACOR

Cumulative Returns on ACOR

-43.3%

10-Year Cumulative Returns

-54.7%

7-Year Cumulative Returns

-66.6%

5-Year Cumulative Returns

-50.7%

3-Year Cumulative Returns

What are the long-term rolling returns for ACOR?

FIve years rolling returns for Acorda Therapeutics.

Annualized Returns

Which funds bought or sold ACOR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-06	Rockefeller Capital Management L.P.	new	-	-	-	-%
2023-02-16	IMA Wealth, Inc.	unchanged	-	13.00	13.00	-%
2023-02-15	Virtu Financial LLC	sold off	-100	-6,000	-	-%
2023-02-14	Royal Bank of Canada	reduced	-4.15	-	-	-%
2023-02-14	CANYON CAPITAL ADVISORS LLC	sold off	-100	-357,000	-	-%
2023-02-14	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-24.58	28,810	58,810	-%
2023-02-14	PRUDENTIAL FINANCIAL INC	reduced	-47.84	6,074	24,074	-%
2023-02-14	TWO SIGMA ADVISERS, LP	added	1.35	7,501	11,501	-%
2023-02-14	Verition Fund Management LLC	reduced	-50.00	2,459	10,459	-%
2023-02-14	TWO SIGMA SECURITIES, LLC	added	554	107,748	114,748	-%

Latest Funds Activity

Are funds buying ACOR calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own ACOR

No. of Funds

Acorda Therapeutics News

Schedule 13G FIlings of Acorda Therapeutics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 10, 2023	davidson kempner capital management lp	0.21%	51,189	SC 13D/A
Feb 14, 2023	canyon capital advisors llc	0.00%	0	SC 13G/A
Feb 13, 2023	renaissance technologies llc	3.57%	868,892	SC 13G/A
Jan 23, 2023	davidson kempner capital management lp	0.24%	59,129	SC 13D/A
Jun 10, 2022	soros fund management llc	0%	0	SC 13G
Jun 10, 2022	davidson kempner capital management lp	0.28%	68,229	SC 13D
Feb 14, 2022	point72 asset management, l.p.	4.1%	464,276	SC 13G/A
Feb 14, 2022	ubs oconnor llc	0%	0	SC 13G/A
Feb 14, 2022	canyon capital advisors llc	5.79%	649,031	SC 13G/A
Feb 11, 2022	renaissance technologies llc	6.38%	714,156	SC 13G/A

ACOR Fair Value

Acorda Therapeutics fair value in different scenarios

The table shows the Fair Value estimates for Acorda Therapeutics for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	1.69 170.31%	1.79 186.31%	2.39 282.28%	3.58 472.62%	4.28 584.58%
Current Inflation	1.63 160.72%	1.72 175.11%	2.29 266.28%	3.38 440.63%	4.02 542.99%
Very High Inflation	1.55 147.92%	1.63 160.72%	2.15 243.89%	3.13 400.64%	3.70 491.81%

Historical Acorda Therapeutics Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Acorda Therapeutics

View All Filings

Date Filed	Form Type	Document
Mar 15, 2023	10-K	Annual Report
Mar 10, 2023	SC 13D/A	13D - Major Acquisition
Mar 09, 2023	8-K	Current Report
Feb 15, 2023	8-K	Current Report
Feb 14, 2023	SC 13G/A	Major Ownership Report
Feb 13, 2023	SC 13G/A	Major Ownership Report
Jan 23, 2023	SC 13D/A	13D - Major Acquisition
Jan 05, 2023	8-K	Current Report
Jan 04, 2023	4	Insider Trading
Dec 23, 2022	8-K	Current Report

Latest Insider Trading transactions for ACOR

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2022-09-03	Sabella Lauren M	sold (taxes)	-601	0.398	-1,511	chief operating officer
2022-09-03	Clem Kerry M	sold (taxes)	-601	0.398	-1,511	chief commercial officer
2022-03-17	COHEN RON	sold	-3,894	1.7014	-2,289	president and ceo
2021-09-03	COHEN RON	sold (taxes)	-17,257	4.38	-3,940	president and ceo
2021-09-03	Morales Robert	sold (taxes)	-1,962	4.38	-448	interim pao & pfo
2021-09-03	Sabella Lauren M	sold (taxes)	-6,618	4.38	-1,511	chief commercial officer
2021-03-03	Sabella Lauren M	acquired	-	-	11,125	chief commercial officer
2021-03-03	BLANK BURKHARD	acquired	-	-	11,125	cmo and head of r&d
2021-03-03	COHEN RON	acquired	-	-	29,000	president and ceo
2020-12-01	LAWRENCE DAVID	sold (taxes)	-737	0.6464	-1,141	chief, bus. ops & pao

About Acorda Therapeutics

Ronald Cohen

www.acorda.com

130

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

ACOR Income Statement

2022-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total net revenues	$ 118,566	$ 129,071
Costs and expenses:
Cost of sales	30,332	40,787
Research and development	5,804	10,420
Selling, general and administrative	106,256	124,399
Amortization of intangible assets	30,764	30,764
Changes in fair value of derivative liability	(37)	(1,156)
Changes in fair value of acquired contingent consideration	(6,659)	2,895
Other operating income	(12,554)
Total operating expenses	153,906	208,109
Operating loss	(35,340)	(79,038)
Other income (expense), net:
Interest and amortization of debt discount expense	(30,200)	(30,035)
Interest income	1,909	5
Realized Gain (Loss) on FX Currency	(8)
Gain on extinguishment of debt	27,142
Other income (expense)	1,250	(6)
Total other income (expense), net	93	(30,036)
Loss before taxes	(35,247)	(109,074)
Benefit from (Provision for) income taxes	(30,669)	5,120
Net loss	$ (65,916)	$ (103,954)
Net loss per share—basic	$ (3.34)	$ (9.79)
Net loss per share—diluted	$ (3.34)	$ (9.79)
Weighted average common shares outstanding used in computing net loss per share—basic	19,707	10,621
Weighted average common shares outstanding used in computing net loss per share—diluted	19,707	10,621
Net Product Revenues
Revenues:
Total net revenues	$ 103,845	$ 114,189
Royalty Revenues
Revenues:
Total net revenues	14,221	$ 14,882
License Revenue
Revenues:
Total net revenues	$ 500

ACOR Balance Sheet

2022-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 37,536	$ 45,634
Restricted cash	6,884	13,400
Trade accounts receivable, net of allowances of $842 and $1,012, as of December 31, 2022 and 2021, respectively	13,866	17,002
Prepaid expenses	4,312	6,574
Inventory, net	12,752	18,548
Other current assets	6,765	999
Total current assets	82,115	102,157
Property and equipment, net of accumulated depreciation	2,603	4,382
Intangible assets, net of accumulated amortization	305,087	335,980
Right of use asset, net of accumulated amortization	5,287	6,751
Restricted cash	255	6,189
Other assets	248	11
Total assets	395,595	455,470
Current liabilities:
Accounts payable	9,809	10,845
Accrued expenses and other current liabilities	23,680	28,605
Current portion of liability related to sale of future royalties		4,460
Current portion of lease liability	1,545	8,186
Current portion of acquired contingent consideration	2,532	1,929
Deferred revenue	384
Total current liabilities	37,950	54,025
Convertible senior notes	167,031	151,025
Derivative liability	0	37
Non-current portion of acquired contingent consideration	38,668	47,671
Non-current portion of loans payable		27,645
Deferred tax liability	44,202	13,930
Non-current portion of lease liability	4,341	4,086
Other non-current liabilities	9,781	5,914
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value per share. Authorized 1,000,000 shares at December 31, 2022 and 2021; no shares issued as of December 31, 2022 and 2021
Common stock, $0.001 par value per share. Authorized 61,666,666 shares at December 31, 2022 and 2021; issued 24,343,239 and 13,249,802 shares, including those held in treasury, as of December 31, 2022 and 2021, respectively	24	13
Treasury stock at cost (5,543 shares at December 31, 2022 and December 31, 2021)	(638)	(638)
Additional paid-in capital	1,029,881	1,023,136
Accumulated deficit	(936,273)	(870,357)
Accumulated other comprehensive loss	628	(1,017)
Total stockholders’ equity	93,622	151,137
Total liabilities and stockholders’ equity	$ 395,595	$ 455,470